Let's take a look at two S&P 500 companies that offer approximately triple the yield of the index. Based on the 27% drop-off in Humira's international revenue, from $1.3 billion in 2018 (biosimilars hit the market late that year) to $948 million in 2019, it's reasonable to expect that the drug's U.S. revenue will experience a similar plunge in 2023, followed by smaller, steadier revenue declines in 2024 and beyond. The good news for AbbVie is that the company is more than ready to make up for Humira's revenue declines with its other two blockbuster immunology drugs, Rinvoq and Skyrizi.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting